不是有數據顯示 VV116 比 Paxlovid 效果更好？副作用更小？難道報道失實？

"Among adults with mild-to-moderate Covid-19 who were at risk for progression, VV116 was noninferior to nirmatrelvir–ritonavir with respect to the time to sustained clinical recovery, with fewer safety concerns."

 

VV116, an oral nucleoside antiviral drug, was shown to be noninferior to nirmatrelvir/ritonavir (Paxlovid) in a phase 3 trial comparing the efficacy and safety of the two therapies in the treatment of symptomatic patients with mild to moderate COVID-19 who were at high risk for progression to severe COVID-19 including death.

 

所有跟帖： 

• 我不能多說。隻能說很多人是這個 -獨行仙人- ♂ (122 bytes) () 01/10/2023 postreply 21:16:00